End-of-day quote
Nigerian S.E.
18:00:00 2024-05-20 EDT
|
5-day change
|
1st Jan Change
|
7
NGN
|
0.00%
|
|
0.00%
|
+33.33%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
2,401
|
3,330
|
6,056
|
6,935
|
7,419
|
9,057
|
Enterprise Value (EV)
1 |
3,932
|
3,282
|
6,236
|
10,592
|
10,070
|
12,386
|
P/E ratio
|
4.1
x
|
4.65
x
|
6.28
x
|
6.61
x
|
4.98
x
|
8.36
x
|
Yield
|
8.16%
|
13%
|
8.55%
|
7.46%
|
6.98%
|
-
|
Capitalization / Revenue
|
0.28
x
|
0.41
x
|
0.64
x
|
0.58
x
|
0.52
x
|
0.46
x
|
EV / Revenue
|
0.46
x
|
0.41
x
|
0.66
x
|
0.89
x
|
0.7
x
|
0.63
x
|
EV / EBITDA
|
2.74
x
|
2.3
x
|
3.2
x
|
4.71
x
|
9.55
x
|
6.52
x
|
EV / FCF
|
18.3
x
|
-6.51
x
|
-19.3
x
|
-3.12
x
|
117
x
|
-20.1
x
|
FCF Yield
|
5.48%
|
-15.4%
|
-5.18%
|
-32.1%
|
0.85%
|
-4.97%
|
Price to Book
|
0.66
x
|
0.57
x
|
0.9
x
|
0.95
x
|
0.9
x
|
1.03
x
|
Nbr of stocks (in thousands)
|
980,000
|
1,725,235
|
1,725,235
|
1,725,235
|
1,725,235
|
1,725,235
|
Reference price
2 |
2.450
|
1.930
|
3.510
|
4.020
|
4.300
|
5.250
|
Announcement Date
|
4/1/19
|
5/12/20
|
3/29/21
|
3/29/22
|
3/29/23
|
4/2/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
8,552
|
8,080
|
9,390
|
11,902
|
14,328
|
19,695
|
EBITDA
1 |
1,435
|
1,427
|
1,950
|
2,250
|
1,054
|
1,900
|
EBIT
1 |
1,007
|
959.7
|
1,393
|
1,687
|
497.9
|
1,308
|
Operating Margin
|
11.78%
|
11.88%
|
14.84%
|
14.17%
|
3.48%
|
6.64%
|
Earnings before Tax (EBT)
1 |
817.9
|
900.9
|
1,248
|
1,460
|
2,084
|
1,520
|
Net income
1 |
585.2
|
716.4
|
964.6
|
1,050
|
1,491
|
1,083
|
Net margin
|
6.84%
|
8.87%
|
10.27%
|
8.82%
|
10.4%
|
5.5%
|
EPS
2 |
0.5971
|
0.4153
|
0.5591
|
0.6084
|
0.8640
|
0.6278
|
Free Cash Flow
1 |
215.4
|
-504
|
-322.9
|
-3,399
|
85.71
|
-615.5
|
FCF margin
|
2.52%
|
-6.24%
|
-3.44%
|
-28.56%
|
0.6%
|
-3.13%
|
FCF Conversion (EBITDA)
|
15.01%
|
-
|
-
|
-
|
8.13%
|
-
|
FCF Conversion (Net income)
|
36.81%
|
-
|
-
|
-
|
5.75%
|
-
|
Dividend per Share
2 |
0.2000
|
0.2500
|
0.3000
|
0.3000
|
0.3000
|
-
|
Announcement Date
|
4/1/19
|
5/12/20
|
3/29/21
|
3/29/22
|
3/29/23
|
4/2/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
1,531
|
-
|
180
|
3,656
|
2,652
|
3,328
|
Net Cash position
1 |
-
|
48.1
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
1.067
x
|
-
|
0.0923
x
|
1.625
x
|
2.515
x
|
1.752
x
|
Free Cash Flow
1 |
215
|
-504
|
-323
|
-3,399
|
85.7
|
-615
|
ROE (net income / shareholders' equity)
|
9.92%
|
15.1%
|
14.9%
|
15%
|
19.2%
|
12.7%
|
ROA (Net income/ Total Assets)
|
7.63%
|
6.82%
|
7.3%
|
6.59%
|
1.75%
|
4.26%
|
Assets
1 |
7,669
|
10,509
|
13,207
|
15,920
|
85,217
|
25,404
|
Book Value Per Share
2 |
3.690
|
3.400
|
3.910
|
4.210
|
4.780
|
5.090
|
Cash Flow per Share
2 |
0.2700
|
0.3100
|
2.300
|
1.670
|
1.680
|
1.960
|
Capex
1 |
556
|
1,125
|
324
|
539
|
1,742
|
1,042
|
Capex / Sales
|
6.51%
|
13.93%
|
3.45%
|
4.53%
|
12.16%
|
5.29%
|
Announcement Date
|
4/1/19
|
5/12/20
|
3/29/21
|
3/29/22
|
3/29/23
|
4/2/24
|
Average target price
7.8
NGN Spread / Average Target +11.43% Consensus |
1st Jan change
|
Capi.
|
---|
| +33.33% | 7.89M | | +37.78% | 723B | | +31.40% | 598B | | -3.51% | 364B | | +19.94% | 331B | | +5.14% | 288B | | +16.47% | 244B | | -4.66% | 208B | | +10.09% | 210B | | +9.32% | 169B |
Other Pharmaceuticals
|